Regarding colorectal CD133+ cancer stem cell-like cells, they are correlated with the invasiveness and differentiation of colorectal tumors, while Pohl et al. correlated their pharmacogenetic profiling with RR (response rate) and PFS (progression-free survival) in patients with colorectal cancer treated with bevacizumab. The gene discussed is PROM1; the disease is colorectal neoplasm.